RT Journal Article
SR Electronic
T1 Prediction of survival for severe Covid-19 patients with three clinical features: development of a machine learning-based prognostic model with clinical data in Wuhan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.27.20028027
DO 10.1101/2020.02.27.20028027
A1 Yan, Li
A1 Zhang, Hai-Tao
A1 Xiao, Yang
A1 Wang, Maolin
A1 Sun, Chuan
A1 Liang, Jing
A1 Li, Shusheng
A1 Zhang, Mingyang
A1 Guo, Yuqi
A1 Xiao, Ying
A1 Tang, Xiuchuan
A1 Cao, Haosen
A1 Tan, Xi
A1 Huang, Niannian
A1 Jiao, Bo
A1 Luo, Ailin
A1 Cao, Zhiguo
A1 Xu, Hui
A1 Yuan, Ye
YR 2020
UL http://medrxiv.org/content/early/2020/03/01/2020.02.27.20028027.abstract
AB The swift spread of COVID-19 epidemic has attracted worldwide attentions since Dec., 2019. Till date, 77,041 confirmed Chinese cases have been reported by National Health Commission of P.R. China with 9,126 critical cases whose survival rate is quite low. Meanwhile, COVID-19 epidemic emergence within the other countries (e.g., Korea, Italy, Japan and Iran) is also remarkable with the increasing spread speed. It plays a more and more important role to efficiently and precisely predict the survival rate for critically ill Covid-19 patients as more fatal cases can be targeted interfered in advanced. However, the survival rates of all the present critically ill COVID -19 patients are estimated manually from over 300 laboratory and clinical features, which inevitably leads to high misdiagnose and missed-diagnose rate due to lack of experience and priori knowledge. As a remedy, we have developed a machine learning-based prognostic model that precisely predicts the survival for individual severe patients with more than 90% accuracy with clinical data collected from Tongji hospital, Wuhan. Significantly, such model only requires three key clinical features, i.e., lactic dehydrogenase (LDH), lymphocyte and High-sensitivity C-reactive protein (hsCRP) out of all 300+ features. The rationality of such mere three features may lie in that they are the representatives of tissue injury-, immunity- and inflammation-typed indices, respectively. From the COVID-19 patient diagnosis aspect, the work actualizes low-cost and prompt criticality classification and survival prediction before targeted intervening and diagnosis, especially for the triage of the large-scale explosive epidemic COVID -19 cases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available once the paper gets accepted. The Python code is available upon request from YY.